Avifavir
The first Favipiravir-based drug in the world approved for the treatment of COVID-19
Research and development of medicines
Development and introduction in manufacture of innovative and reproduced synthetic and biotechnological Medicinal products "on a turn-key basis"
Investment activities
Investing in the development of innovative drugs; joint development of the projects of the ChemRar portfolio on partner terms; licensing and transfer of rights to the results of intellectual activity

«ChemRar» High-Tech center:

We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:

• Using experience and global standards at all stages of creation of a novel medicine;

• Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;

• Applying our knowledge to search for optimal solutions for our partners.

NEWS

The results of the two phases of the clinical trial of Avifavir for coronavirus treatment were presented at the “COVID-19: Pandemic of the XXI Century” International Congress held in Ufa on November 13–14. More than 3,500 experts from 8 countries (Russia, China, USA, Germany, Uzbekistan, Kazakhstan, Tajikistan, and Ukraine) took part in the ...

20.11.2020
Under the Government order on financing the purchase of drugs for the treatment of outpatients with the COVID-19 infection, the drug will be free of charge; The joint venture formed by RDIF and ChemRar Group will double the drug’s production volume to 200,000 packs of Avifavir per month; The permanent registration certificate for the drug as a ...

09.11.2020
 Efficacy of favipiravir-based drugs against COVID-19 has been confirmed by clinical trials in Russia and Japan Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan have already received Avifavir, deliveries to 17 more countries are expected Moscow, September 24, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s ...

24.09.2020
Moscow, September 23, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce measures to increase the availability of Avifavir, the world's first favipiravir-based drug registered against coronavirus infection and Russia’s first drug approved for the treatment of COVID-19. Efficacy of ...

23.09.2020
All news
Get the latest pharma news delivered to your inbox
  
I agree to the processing of personal data. Privacy policy